C orbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, dipping to $10.43. With a beta of 2.64 and a trading range of $7.49 to $61.90 over the past year, InvestingPro ...

Participants in HNSCC, cervical, and mUC tumors are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts. Price Action: CRBP stock is down 8.23% at $8.70 at the last check on Friday.

1 Day CRBP -7.46% DJIA 0.08% Russell 2K -0.78% Health Care/Life Sciences -0.37% ...

Shares of NASDAQ CRBP opened at $6.79 on Monday. Corbus Pharmaceuticals has a twelve month low of $6.54 and a twelve month high of $61.90. The firm has a market cap of $82.70 million, a P/E ratio ...

(RTTNews) - Corbus Pharmaceuticals Holdings, Inc.(CRBP), has reported promising data for CRB-701 or SYS6002, a next-generation Nectin-4 targeting antibody-drug conjugate or ADC, at the 2025 ...

Find the latest Corbus Pharmaceuticals Holdings CRBP analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $65.00. The company’s ...

NASDAQ CRBP opened at $6.79 on Thursday. Corbus Pharmaceuticals has a 12 month low of $6.54 and a 12 month high of $61.90. The stock’s fifty day moving average price is $9.98 and its 200-day ...

Investors in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 17, ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $42.00. The company’s shares closed last ...